Nowadays, DS-AD can be diagnosed even in the preclinical period by using positron emission tomography (PET) for amyloid and tau as well as by fluid biomarker changes of decreased Aβ42 and elevated p-tau in cerebrospinal fluid (CSF) at specialized medical institutions [8–10]. Here, MAPT is linked to Alzheimer disease.